Successful retreatment of HCV relapse patient with 4 weeks long sofsobuvir, ribavirin, and daclatasvir combination: Case Series
Abstract
Abstract Views: 188
Hepatitis-C virus (HCV) is an enveloped RNA virus that currently infects more than 180 million people, worldwide. Interferon therapy was previously used as a standard therapy for HCV. Now it has been replaced with an interferon-free therapy or the direct acting antiviral (DAA) drug therapy. Although the DAA drug therapy is a potent strategy which has an excellent efficacy against the HCV infection with a majority of patients achieving sustained virological response (SVR), we report here three patients who experienced relapse after a 6-month long DAA drug therapy. The patients experienced relapse after receiving sofosbuvir (400mg) and ribavirin for 6 months. All three patients were later successfully treated with sofosbuvir, ribavirin, and daclatasvir combination. The current study highlights that the retreatment combination of sofosbuvir, ribavirin, and daclatasvir is more efficacious in the Pakistani population where practitioners are still using sofosbuvir and ribavirin.
Copyright (c) The Authors
Downloads
References
LavanchyD. Evolving epidemiologyof hepatitis C virus. Clin Microbiol Infect. 2011; 17(2):107-115.https://doi.org/10.1111/j.14690691.2010.03432.x
Hajarizadeh BJ, Grebely J, Dore GJ. Epidemiology andnatural history of HCV infection. Nature Rev Gastroenterol Hepatol. 2013;10(9):553-562.https://www.nature.com /articles/nrgastro.2013.107.pdf?origin=ppub
Manns M, WedemeyerH, CornbergM. Treating viral hepatitis C: Efficacy, side effects, and complications. Gut. 2006;55(9):1350-1359.http://dx.doi.org/10.1136/gut. 2005.076646
PockrosPJ, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterol.2016;150(7):1590-1598.https://doi.org/10.1053 /j.gastro.2016.02.078
SuwanthawornkulT, AnothaisintaweeT, Sobhonslidsuk A, et al.Efficacy of second generation direct-acting antiviral agents for treatment naïve hepatitis C genotype 1: A systematic review and network meta-analysis. PloS one. 2015 Dec 31;10(12):e0145953. https://doi.org /10.1371/journal.pone.0145953
Toyoda H, et al. Safety and efficacyof dual direct-acting antiviraltherapy (daclatasvir andasunaprevir) for chronic hepatitis Cvirus genotype 1 infection inpatients on hemodialysis. JGastroenterol. 2016;51(7)141-147.
Johnson TM, et al. Clinicalexperience with dolutegravir/abacavir/lamivudine in HIV–HCVco-infected patients treated with asofosbuvir-based regimen—safetyand efficacy. HIV Clin Trials.2016;17(6):242-245.https://doi.org/10.1080/15284336.2016.1248625
Martinello M, et al. Sofosbuvir andribavirin for six weeks is noteffective among people with acuteand recently acquired HCVinfection: The DARE-C II study.Hepatol. 2015;62(1):741-742.
Pawlotsky JM. Hepatitis C VirusResistance to Direct-Acting AntiviralDrugs in Interferon-Free Regimens.Gastroenterol. 2016; 151(1):70-86.https://doi.org/10.1053/j.gastro.2016.04.003
Donaldson EF, et al. Clinicalevidence and bioinformaticscharacterization of potential hepatitisC virus resistance pathways forsofosbuvir. Hepatol. 2015;61(1):56-65.https://doi.org/10.1002/hep.27375
Pawlotsky JM. Treatment failureand resistance with direct‐actingantiviral drugs against hepatitis Cvirus. Hepatology. 2011;53(5):1742-1751.https://doi.org/10.1002/hep.24262
Costantino A, et al. Naturallyoccurring mutations associated withresistance to HCV NS5Bpolymerase and NS3 proteaseinhibitors in treatment-naïvepatients with chronic hepatitis C.Virol. 2015;12(1):186-172.
Afdhal N, et al. The Effect of LiverFibrosis and Cirrhosis on SVR in4913 Patients With Hepatitis C:Results From The WIN-R Trial.Gastroenterol. 2006;130(4):212-265
Abergel A, et al., Peginterferonalpha‐2b plus ribavirin for treatmentof chronic hepatitis C with severefibrosis: Amulticentre randomizedcontrolled trial comparing twodoses of peginterferon alpha‐2b. JViral Hep. 2006;13(12):811-820.https://doi.org/10.1111/j.1365-2893.2006.00768.x
Im GY,DieterichDT. Direct-actingantiviral agents in patients withhepatitis C cirrhosis. GastroenterolHepatol. 2012;8(11):727-765.[16]Wahid B,Wasim M, Saleem K,Waqar M, Wahid K, Hussain M,Idrees M. Poor glycemic control andabrupt onset of diabetes in HCVpatients receiving direct-actingantiviral drugs: case series. FutureVirol. 2018;13(08):525-8. https://doi.org/10.2217/fvl-2017-0147
Wahid B. Hepatotoxicity andvirological breakthrough of HCVfollowing treatment with sofosbuvir,daclatasvir, and ribavirin in patientspreviously treated for tuberculosis. JMed Virol. 2019;91(12):2195-7.https://doi.org/10.1002/jmv.25557
Saleem et al.25
Wahid B, Shami K, Joiya SA, et al.Comparing the risk ofhypothyroidism in HCV patientstreated with different DAA drugscombinations(sofosbuvir+ interferon+ribavirin and sofosbuvir+daclatasvir+ ribavirin). J Med Virol.2020;92(12):3868-70.https://doi.org/10.1002/jmv.25931
Copyright (c) 2020 Komal Saleem, Amjad Ali, Shazia Rafique, Noshaba Rani, Braira Wahid
This work is licensed under a Creative Commons Attribution 4.0 International License.
BSR follows an open-access publishing policy and full text of all published articles is available free, immediately upon publication of an issue. The journal’s contents are published and distributed under the terms of the Creative Commons Attribution 4.0 International (CC-BY 4.0) license. Thus, the work submitted to the journal implies that it is original, unpublished work of the authors (neither published previously nor accepted/under consideration for publication elsewhere). On acceptance of a manuscript for publication, a corresponding author on the behalf of all co-authors of the manuscript will sign and submit a completed the Copyright and Author Consent Form.
